2015 BIO International Convention - Australia Pavilion Exhibitor Directory Philadelphia, Pennsylvania - AusBiotech
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Australia Pavilion
Exhibitor Directory
2015 BIO International
Convention
Philadelphia, Pennsylvania
15-18 June 2015
1
Contents
About Australian life sciences 3
AusBiotech 5
Department of Industry, Innovation and Science 6
State Government of Victoria 7
Queensland Government 8
Callaghan Innovation 9
Life Sciences Queensland Limited 10
MTPConnect 11
Queensland University of Technology 12
360biolabs 13
Alliance for Safe Biologic Medicines (ASBM) 14
Australian Regenerative Medicine Institute 15
Burnet Institute 16
Paradigm BioPharmaceuticals 17
CMAX 18
Datapharm 18
DibbsBarker 19
Marilyn Careers 19
Medicines Australia 20
Plunkett Consulting Group 20
Neuroscience Trials Australia 21
Nucleus Network 21
Quintiles IMS 22
Regeneus 22
Vudbenk Life Sciences 23
Australian organisations at BIO 24
AusBiotech 2017 national conference 27
2
Australia: a thriving life science hub
with global reach
Why Australia? The R&D Tax Incentive, Australia’s flagship
innovation program, offers increased access
Australia is a world-leading location for the for international companies and provides
life sciences and has been ranked among the businesses with generous tax offsets for
top five in biotechnology innovation for three eligible R&D activity. Other government
consecutive years. Australian Government support programs include the Medical
policy and funding programs seek to advance Research Future Fund (MRFF), to support
Australia’s strength in medical technology, research and innovation in medical research;
digital health, agritech and foodtech, the Biomedical Translation Fund (BTF),
therapeutics, regenerative medicine and stimulating private investment in the sector;
other key areas of the life sciences. and the MTPConnect Project Fund Program,
AusBiotech, Australia’s life science providing funding to projects in the medtech,
organisation, plays a central role in biotech and pharmaceutical sector.
facilitating the global development of the
Australian life sciences industry, with a
network of over 3,000 members and leader World-class clinical trial capabilities
of the Australian delegation to BIO.
Pharmaceutical, biotechnology and medical
device companies commence around 1,000
A robust and rapidly growing industry new clinical trials each year to represent an
AU$1 billion investment. Our strength in
The Australian ASX-listed life science industry
clinical trials is characterised by:
is valued at AU$100.042 billion and
comprises of around 100 companies. The
Quality medical research
industry raised AU$1.384 billion in capital in
infrastructure, a skilled workforce and
2016 and is expected to grow by 4.4%
world-class healthcare system;
annually, reaching a projected AU$8.67
billion in aggregate revenues by 2021. It
employs over 48,000 Australians in high-
An efficient regulatory pathway and
compliance with high international
value STEM jobs and is a leading location for
standards for data;
life science companies in the Asia Pacific
region, with around 300 biotech and 400
medtech companies.
Intellectual property, ranked 11th
most secure in the world; and
Global trade and investment partner An ethnically diverse, English-
speaking population and close
Australia has benefitted from 26 consecutive
proximity to Asia.
years of economic growth and the country’s
economic growth rate is forecast to be the
highest among major advanced economies
over the next five years.
3
Insert BIO flyer here (Australian life science industry)
4
About AusBiotech
Contact Glenn Cross Our global investment program
Chief Executive Officer promotes investment in the
Phone +61 3 9828 1400 Australian life science industry,
including events around the globe
Email admin@ausbiotech.org
and resources for investors and
Website ausbiotech.org companies.
Australia’s largest industry network The Australian Life Science Innovation
AusBiotech is Australia’s industry Directory contains a database of
organisation, working on behalf of members companies to inform global potential
for more than 30 years to provide partnerships.
representation and services to promote the We advocate for policy reform in tax,
global growth of the Australian life sciences.
clinical trials, intellectual property,
AusBiotech is a well-connected network of regulation and more to sustain
over 3,000 members in the life sciences,
Australia’s global competitive
including therapeutics, medical technology
advantage in the life sciences.
(devices and diagnostics), food technology
and agricultural, environmental and AusBiotech’s mission
industrial biotechnology sectors.
AusBiotech’s mission is to foster a growing,
We have representation in each Australian strong and profitable biotechnology and life
state, which provides a national network to science industry in Australia through
support members, which include life science representation, advocacy and the provision
companies (from startups to mature of services and benefits to its members to
multinationals), research institutes and help the industry realise its nationally
universities, specialist service professionals, important economic potential.
corporate, institutional, individual and
AusBiotech at BIO
student members from around Australia and
globally. The Australian Wine Tasting Event,
Strengthening the Australian life sciences Tuesday 20 June at the Australian
Pavilion.
AusBiotech is dedicated to the development,
growth and prosperity of the Australian AusBiotech/Biocom MoU,
biotechnology industry, by providing Wednesday 21 June.
initiatives to drive sustainability and growth, Global Innovation Hubs presentation,
outreach and access to markets, and Wednesday 21 June.
representation and support for members
nationally and around the world.
5
Department of Industry,
Innovation and Science
Contact Ashley Bates
Sector Director, Medical Technologies and Pharmaceuticals
Entrepreneurs’ Programme
Phone 1300 651 010 (within Australia only) or +61 2 6283 2211 (International)
Email Ashley.Bates@ep.industry.gov.au
Website business.gov.au or industry.gov.au
The Australian Government Department of Accelerating Commercialisation -
Industry, Innovation and Science’s vision is to experienced private sector Advisers help
enable growth and productivity for globally business commercialise novel products,
competitive industries. To help realise this services and processes. This may include
vision, the Department has four key matched funding.
objectives: supporting science and
commercialisation, growing business Business Management - experienced
investment and improving business private sector Advisers and
capability, streamlining regulation and Facilitators review business
building a high performance organisation. operations including business
direction, strategy, growth
The Department focuses on innovation and opportunities and supply chains. They
ship through the Entrepreneurs’ provide a report with strategies for
Programme — one of many Government improvement and work with the
initiatives supporting business productivity business to make them happen.
and growth in Australia.
Incubator Support - assists New and
The Entrepreneurs’ Programme offers Existing Incubators to improve the
independent and tailored advice and prospects of Australian start-ups
assistance to businesses, researchers and achieving commercial success in
entrepreneurs through a network of international markets by supporting
experienced private sector Advisers and Australia’s innovation ecosystem.
Facilitators across several sectors including
Medical Technologies and Pharmaceuticals. Innovation Connections -
This includes working together to get experienced Facilitators identify
innovative products, processes or services knowledge gaps that prevent
into markets. business growth. The outcome is an
Innovation Facilitation Report and
The Programme delivers support to improve may include co-funding for research
productivity and competitiveness through activities.
four elements:
6
State Government of Victoria
Contact Dr Phil Davies
Senior Trade Manager — Medical Technologies, Biotechnology and
Pharmaceuticals
Phone +61 3 9561 9481 or +61 423 90 2083
Email phil.davies@ecodev.vic.gov.au
Website tradeandinvestment.vic.gov.au
COMPANY PROFILE
The Department of Economic Connected to global markets,
Development, Jobs, Transport and supported by a open and stable
Resources (DEDJTR) is the Victorian economy, together with a skilled and
Government’s lead agency for to educated workforce.
sustainably develop the Victorian
economy and grow employment.
Australia's undisputed leader in
medical research with a network of
A global biotechnology hub, leading hospitals, medical research
consisting of companies known for institutes and world-class universities
their excellence and innovation with
world's best practice for clinical trials
Maintains a global network of 20
business offices to tailor a service
and drug development.
package that suits your needs.
7
Queensland Government
Contact Stewart J MacIntyre
Director, Science Capability, Engagement and Collaboration
Department of Science, Information Technology and Innovation
Phone +61 7 3170 5856
Email stewart.macintyre@dsiti.qld.gov.au
Website qld.gov.au/lifesciences / twitter.com/qldscience
COMPANY PROFILE
The Queensland Government is focused on development and innovation between 1998–99
strengthening our economy through science and and 2016–17.
innovation. We are committed to boosting
scientific research in partnership with universities The Queensland Government’s Advance
and industry. Queensland’s globally competitive Queensland initiative is taking the state’s life
life sciences sector taps into the state’s unique sciences capability to the next level, and opening
natural resources, with successes in health, up new partnership and investment opportunities
agriculture, environment and industrial for international collaborators and investors.
biotechnology. Through this A$405 million investment, we
continue to actively support the state’s life
The Department of Science, Information sciences industry through:
Technology and Innovation (DSITI) supports
universities and research organisations, and links investing in biotechnology research and
with businesses, peak bodies and other state and its commercialisation
federal government agencies to foster the
development of a sustainable life sciences sector. supporting world-class research precincts
Queensland is home to 9 universities, and over 30 and centres of excellence
world-class research facilities specialising in
biotechnology, food and agriculture, and health translating knowledge from key
and medicine (including tropical health). For international alliances into new products
further information, search the Queensland
and services.
Science Capability Directory at www.qld.gov.au/
lifesciences. Queensland is a highly attractive knowledge hub
for global research and business collaboration,
Queensland’s world-class infrastructure supports a partnering with experts across all life sciences to
vibrant and growing scientific community, with a access cutting-edge technology, intellectual know-
number of demonstrated commercial successes, how and new markets.
including the GardasilTM vaccine. The state boasts
252 companies in the life sciences industry with 86
core biotechnology companies, and an investment
of A$5.7 billion to boost Queensland’s research,
8
Gold Partner
Callaghan Innovation
Contact Kimberlee Jordan
National Network Manager Biotechnologies
Callaghan Innovation
Phone +64 21 0209 8687
Email kimberlee.jordan@callaghaninnovation.govt.nz
Website callaghaninnovation.govt.nz
Contact Zahra Champion
Chief Executive Officer
NZBIO
Phone +64 21 899 732
Email ceo@nzbio.org.nz
Website nzbio.org.nz
PROFILE
New Zealand’s mission to BIO 2017 is being led by Callaghan Innovation and NZBIO. The
innovative biotech businesses in the mission are: Upside Biotechnologies; Ubiquitome;
Polybatics; HoneyLab New Zealand Pharma and Hikurangi Enterprises.
Callaghan Innovation is the New Zealand Government’s business innovation agency. We
grow New Zealand’s economy by helping New Zealand businesses succeed through
technology. Callaghan Innovation provides a range of services and R&D grants to businesses,
has its own R&D facilities and plays a critical role in building and strengthening New
Zealand’s innovation capability. Callaghan Innovation also provides a gateway to innovation
in New Zealand by connecting the rest of the world to New Zealand’s innovative companies,
research institutes, incubators, universities and commercialisation offices.
NZBIO facilitates New Zealand’s growing role in providing modern, globally relevant,
biotechnology products. The application of these technologies can help solve many of the
world’s problems. We are the sector’s leading representative and advocate, and act as an
enabler, influencer and direction setter, as well as the critical network hub, across a broad
spectrum of biotech disciplines.
9
Gold Partner
Life Sciences Queensland Limited
Contact Clare Bain
Operations Manager
Phone +61 7 3331 3944
Email cblain@lsq.com.au
Website lsq.com.au
COMPANY PROFILE
Life Sciences Queensland Limited (LSQ) is an Australian peak industry body that promotes
and supports all segments of the life sciences and provides the opportunity for industry
stakeholders to come together to cooperate to innovate to grow their businesses and help
create a dynamic, internationally competitive and sustainable life sciences industry in
Australia. LSQ is helping to shape the strategic direction of the industry, by influencing
public policy and promoting the role of innovation in economic development. We also
provide members with services, market intelligence and access to an international network
of life sciences organisations with the aim of identifying new business opportunities and
accelerating business growth.
LSQ is an industry-led vehicle working to enhance its 170+ members’ national and
international reputation as being at the centre of commercial and research excellence in life
sciences.
LSQ engages the full spectrum of stakeholders in the life sciences industry, to assist the
growth of individual organisations and industry segments, and to build the profile, capacity
and capability of the sector to help ensure long term economic, social and environmental
benefits to the sector and its members. The primary objectives of LSQ are to:
Develop the industry by supporting local industry forums and providing members
with tools to accelerate their business growth;
Create new business opportunities for members through market outreach (e.g.
business development services, event management, a co-ordinated approach to
international business meetings) that members cannot readily or cost-effectively
achieve on their own; and
Play a leading role in dealing with governments at all levels and influencing public
policy so as to help ensure sustainable growth of the Australian life sciences
industry.
Sub-sectors that are illustrative of the Australian life sciences industry include:
Human healthcare (pharmaceuticals or drug discovery, complementary medicines,
functional foods/beverages, medical devices and diagnostics);
Industrial biotechnology (including bio-mining and bio-energy);
Agricultural and environmental biotechnology;
Animal health; and
Marine biotechnology.
10Gold Partner
MTPConnect
Contact Dr Sandhya Tewari
General Manager International & Government
Phone +61 406 405 690
Email sandhya.tewari@mtpconnect.org.au
Website mtpconnect.org.au
COMPANY PROFILE
MTPConnect is an independent, not-for-profit organisation championing a sector-led
approach to support the growth of Australia’s flourishing medical technology, biotechnology
and pharmaceutical ecosystem. MTPConnect was established as part of the Australian
Federal Government $250 million Industry Growth Centres Initiative, in acknowledgement of
the sector’s international value and importance to the Australian economy.
MTPConnect can bridge the international gap by connecting international and Australian
companies and researchers to foster collaboration and product development, sharing of
expertise and best practice, and access to joint funding through grants and investment,
working closely with Austrade.
Visit mtpconnect.org.au to become a Network Associate and take advantage of early access
to industry insights, news, events, and opportunities for collaboration and promotion.
11Gold Partner
Queensland University
of Technology
Contact Michael McArdle
Director-Office of Research
Phone +61 7 3138 5376
Email m.mcardle@qut.edu.au
Website qut.edu.au
COMPANY PROFILE
Queensland University of Technology (QUT) is an internationally recognised provider of high-
impact medical and agricultural biotechnology research. Our high quality, end-user relevant
research and development programs are delivered through:
The Institute of Health and Biomedical Innovation (IHBI), a multidisciplinary research
institute devoted to improving the health of individuals and communities through
research innovation. IHBI has world leading expertise in areas such as prostate
cancer, infectious diseases, burns and wound management, genomics, orthopaedics
and trauma, vision, medical robotics and devices and biofabrication.
The Centre for Tropical Crops and Biocommodities, which brings together a unique
mix of international expertise in tropical crop biotechnology, biofuels and
biomaterials, industrial chemistry and process engineering to create horizontally
integrated research and development from laboratory through pilot plant and field
trial to commercial feasibility.
QUT’s technology transfer and commercialisation company, qutbluebox, aims to bring the
benefits of QUT's research discoveries to the global market via the identification, protection
and commercialisation of intellectual property.
12Silver Partner
360biolabs
Contact Business Development
Phone +61 3 9282 2285
Email bd@360biolabs.com
Website 360biolabs.com
COMPANY PROFILE
360biolabs is an accredited (ISO 15189, ISO / IEC 17025 and OECD Principles of GLP) contract
research organisation (CRO) focused on providing specialist laboratory support for the rapid
preclinical and clinical development of our client’s therapeutics, vaccines and diagnostics. It
is an Australian company based in Melbourne. The management and staff at 360biolabs
have extensive experience of drug, vaccine and diagnostic R&D and a proven international
track record of successful project delivery. We share a passion for bringing your new
medical interventions closer to the market via the conduct of high quality, competitive
science, conducted in compliance with internationally recognised standards and suitable for
supporting regulatory submissions worldwide.
We provide expert support for the development of vaccines, small molecule and biological
drugs, diagnostics and other interventions across multiple disease areas with a focus on the
measurement of relevant biomarkers as well as assay development and validation. We offer
a diverse array of assays, including live virus assays (such as PRNT50 assays), small and large
molecule pharmacokinetics and pharmacodynamics, Luminex-based multiplex, ADA,
ELISPOT, ELISA, and FACS, amongst others. We look forward to discussing your assay
requirements.
13Silver Partner
Alliance for Safe
Biologic Medicines (ASBM)
Contact Michael Reilly
Executive Director
Phone +1 703- 971-1700
Email michael@safebiologics.org
Website safebiologics.org
COMPANY PROFILE
A Global Voice for Patients
Founded in 2010, the Alliance for Safe Biologic Medicines (ASBM) is an organisation of
physicians, patient advocates, pharmacists, researchers and manufacturers of both
innovator biologics and biosimilars. We share the common goals of improving patient access
to biologic therapies, promoting high safety and quality standards, as well as keeping
physicians and patients in charge of treatment decisions. ASBM has 66 member groups
spread across five continents, including Australia.
Bringing Patient and Healthcare Provider Perspectives to the Biosimilar Policy Discussion
ASBM works to educate policymakers and regulators worldwide as they craft biosimilar
policy at the state/provincial, national, and international levels. ASBM provides
policymakers with perspectives from physicians, pharmacist, and patients that rely on safe
and effective medicines.
ASBM has gathered survey data from biologic prescribers and pharmacists in twelve
countries with the most recent survey released in Australia in 2016. ASBM has worked with
its coalition to present physician, pharmacist, and patient perspectives to national
regulators across the globe including the World Health Organization (WHO), the European
Union (EU) and the Australian Therapeutic Goods Administration (TGA).
14Silver Partner
Australian Regenerative
Medicine Institute
Contact Silvio Tiziani
Chief Operating Officer
Phone +61 4 1853 6209
Email silvio.tiziani@monash.edu
Website armi.org.au
COMPANY PROFILE
The Australian Regenerative Medicine Institute was opened in 2009 to deliver on the
promise of regenerative medicine.
It has built upon the work of Monash University pioneers in IVF and stem cells to attract
global regenerative science leaders and a new generation of young, creative researchers to
inspire and to lead the cutting edge of this exciting new therapeutic field.
Our Institute explores new research methods and test new ideas that will allow us to bring
revolutionary breakthroughs on heart disease, muscular dystrophy, diabetes, multiple
sclerosis, brain injury and autoimmune disorders from bench to beside faster.
Research at ARMI is structured along four integrated Discovery Pipelines aimed at driving
discoveries from the lab bench to the patient:
Heart and muscle development and regeneration
Immunity and Regeneration
Stem cells and Regeneration
Neural regeneration
The pipelines exploit the evolutionary and developmental diversity of research platforms
and systems biological approaches within the Institute to explore specific aspects of the
regenerative process.
Each pipeline engages established leaders of international standing who support young
groups at a creative stage of their careers.
15Silver Partner
Burnet Institute
Contact Geoff Drenkhahn
Head, Business Development and Commercial Operations
Phone +61 3 9282 2263 (office) / +61 410 486 692 (mobile)
Email geoff.drenkhahn@burnet.edu.au
Website burnet.edu.au
COMPANY PROFILE
The MacFarlane Burnet Institute for Medical Research and Pubic Health brings together a
highly diverse group of medical researchers, public health professionals and international
development experts to help solve significant global health problems. The Institute is unique
in Australia as the only formally dual accredited medical research organisation with the
National Health and Medical Research Council (NHMRC) and as a non-government
organisation (NGO) with the Australian Department of Foreign Affairs and Trade – Australian
Aid.
Burnet’s vision is equity through better health and has particular expertise and a
programmatic focus on disease elimination (malaria, HIV, hepatitis viruses and tuberculosis),
maternal and child health, behaviours and health risk, healthy ageing, and health security,
with a focus on accelerating the translation of research, discovery and evidence into
sustainable health solutions. This includes developing new diagnostics, vaccines, and
treatments, rapid diagnostic technology and vaccine development programs. The Institute
has a strong collaborative portfolio, both with research and industry partners and has four
spin off entities to commercially develop advanced technologies in Point of Care diagnostics,
vaccine development and clinical trial support services.
Based at the Alfred Medical Research and Education Precinct in Melbourne, Australia, the
Institute has offices and representatives in China, Myanmar, Papua New Guinea and Lao
PDR; as well as significant program activities across Asia, the Pacific and eastern Africa.
16Silver Partner
Paradigm BioPharmaceuticals
Contact Paul Rennie
CEO
Phone +61 437 778 300
Email prennie@paradigmbiopharma.com
Website paradigmbiopharma.com / linkedin.com/company-beta/17963763
COMPANY PROFILE
Paradigm Biopharma (PAR) listed on the ASX in August 2015. Our focus is on repurposing
pentosan polysulphate sodium (PPS), an FDA approved drug that has a long track record of
treating inflammation, having been used to treat interstitial cystitis and for preventing DVT.
We focus on the application of PPS in diseases sustained by inflammation, where a key
feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Our major clinical applications currently under investigation are:
Orthopaedic: bone marrow edema and osteoarthritis
Respiratory: allergic rhinitis and asthma
Chronic obstructive pulmonary disease
Arthritogenic alphaviruses: Ross River fever and chikungunya
By working closely with the proprietary manufacturer of PPS, we are able to leverage
substantial knowledge and expertise from earlier regulatory filings. With this foundation,
Paradigm Biopharma minimises its risk profile, and can accelerate the drug development
cycle at significantly reduced costs.
We have a focused, multidisciplinary management team with broad fundamental
experience of complex diseases and networked pathways. We also have deep knowledge of
taking drugs through clinical trials and structuring partnerships with small and large
corporations, and have established strong and successful collaborations with the leading
clinical researchers and manufacturers in the field.
17Bronze Partners
CMAX
Contact Jane Kelly
CEO
Phone +61 8 7088 7900
Email jane.kelly@cmax.com.au
Website cmax.com.au
COMPANY PROFILE
CMAX Clinical Research is a dedicated, 50-bed, self-contained clinical trial facility which specialises in
Phase I-II studies, including first-time-in man studies for global pharmaceutical and biotechnology
companies. CMAX also participates in a wide range of Phase III-IV studies as an investigative site. CMAX
has over 23 years’ experience, making it Australia’s first established dedicated Phase I facility. CMAX
moved to brand new custom-built facilities in April 2016, in close proximity to Adelaide’s new BioMed
City. CMAX offers quality, portable data that is acceptable to international regulatory authorities, with
fast start-up timelines and a high level of responsiveness.
Datapharm
Contact Luke Edington
Clinical Project Manager
Phone +61 408 206 011
Email luke.edington@datapharmaustralia.com
Website datapharmaustralia.com
COMPANY PROFILE
Datapharm is Australia’s original full service contract research organisation (CRO) (est. 1987)
providing clinical trial services such as clinical trial site selection, regulatory and site set-up,
clinical trial monitoring services, data management, statistics, medical and scientific writing,
medical monitoring and pharmacovigilance, patient recruitment, quality control processes
and GCP auditing. All phases (Phase I, Phase II, Phase III and Phase IV). Ask us about our
therapeutic area experience.
We support, biotech, pharma and medical device companies.
18Bronze Partners
DibbsBarker
Contact Anna Feros
Partner
Phone +61 411 606 220
Email anna.feros@dibbsbarker.com
COMPANY PROFILE
DibbsBarker is a leading law firm in life sciences in Australia. As advisor to leading Australian
and global clients such as QIMR Berghofer, Kyowa Hakko Kirin, Nanosonics, ResMed,
Regeneus, CRCs, CROs and many universities, we have deep industry knowledge and
relationships supported by scientific qualifications of members of our team.
We assist clients at every phase, from supporting early stage R&D, clinical trials, capital
raisings and IP licensing, through to advising on supply chain, tendering, regulatory
compliance, M&A and litigation. We work with research institutes on spin-outs and
commercial arrangements, as well as providing targeted due
Marilyn Careers
Contact Marilyn Jones
Managing Director
Phone +61 40 100 3553
Email marilyn@marilyncareers.com
Website marilyncareers.com
COMPANY PROFILE
Marilyn Careers for Executive Search Recruitment. Marilyn Careers are experienced in the
'Search & Select' process. We search and find the best candidate for your role. We also offer
HR recruitment services tailored to your needs including advertising, screening, interviewing
& reference checking.
Positions & Industry sectors include; Business Development, Pharmaceutical, Commercial
Operations, Healthcare, CEO & CFO, Biotechnology, Technical & Engineering, Devices &
Diagnostics, Sales & Marketing, Quality Management, Project Management, Applications
Support.
In addition we also offer a comprehensive outplacement job search preparation program to
ensure that staff have the necessary skills to move on to the next step in their careers.
Executive Candidate/Employee services: Résumé advice, Résumé rewrites, Job search
assistance, LinkedIn profile writing & Interview skills training.
19Bronze Partners
Medicines Australia
Contact Elizabeth de Somer
Director, Policy and Research
Phone + 61 (0)2 6122 8525
Email elizabeth.desomer@medicinesaustralia.com.au
Website medicinesaustralia.com.au
COMPANY PROFILE
Medicines Australia represents the discovery-driven pharmaceutical industry in Australia.
Our member companies invent, manufacture and supply innovative medicines and vaccines
to the Australian community. The Australian innovative pharmaceutical industry exports $3.2
billion in medicines each year, supports nearly 50 thousand jobs and invests heavily in
research and development. The medicines industry fosters extraordinary talent, which
translates promising scientific research into new treatments. Medicines Australia and our
members are part of a thriving global healthcare environment. Constructive collaboration
between industry and governments is key to growing Australia’s innovative medicines trade.
Foreign investment is a key driver of economic growth
and prosperity for Australia.
Plunkett Consulting Group
Contact Greg Plunkett
Managing Director
Phone +61 3 9898 6353 / +61 410 552 020
Email info@plunkettconsulting.com.au
Website plunkettconsulting.com.au
COMPANY PROFILE
Plunkett Consulting Group is a biopharmaceutical and medical device development
organisation, providing expertise in regulatory affairs and clinical research. Our highly
experienced team supports the advancement of product development, from pre-clinical
evaluations, manufacturing and CMC evaluation, human clinical studies and regulatory
approval. Our personnel have far-reaching knowledge with international regulatory
standards, and direct management of multi-national projects in a variety of therapeutic
areas. We have an exceptional network of clinical investigation sites that have proven
ability to generate high quality data. By combining regulatory and clinical skills, we have
the capability to guide the R&D program.
20Bronze Partners
Neuroscience Trials
Australia
Contact Tina Soulis
General Manager
Phone +61 429 300 705
Email tina.soulis@florey.edu.au
Website neurotrialsaustralia.com
COMPANY PROFILE
Neuroscience Trials Australia is an Australian-based contract research organisation
specialising in neuroscience clinical research.
Areas of expertise include stroke and stroke-related conditions, multiple sclerosis, epilepsy,
movement disorders such as Parkinson`s disease, spinal cord injuries, Huntington`s disease,
neurosurgery, pain, neuromuscular disease, Motor Neurone Disease/ALS and migraine.
As a business within The Florey Institute of Neuroscience and Mental Health (The Florey), we
have strategic alliances with many therapeutic disease groups and we can provide access to
key opinion leaders, sites and clinical trial expertise through a range
of tailored services.
Nucleus Network
Contact Cameron Johnson
Chief Executive Officer & Managing Director,
Phone +61 414 346 382
Email c.johnson@nucleusnetwork.com.au
Website nucleusnetwork.com.au
COMPANY PROFILE
Nucleus Network conducts phase I clinical trials for international pharmaceutical and
biotechnology Companies. Established in 2004, Nucleus Network has successfully
conducted over 500 phase I clinical trials including first-time-in human (FIH), single
ascending (SAD) and multiple ascending dose (MAD), drug interaction, food effect,
biosimilar, bioequivalence, thorough QTc, ethnopharmacology and absorption,
distribution, metabolism, and excretion (ADME) studies. Nucleus Network is considered the
market leader for phase I clinical trials in Australia, with extensive experience with both
biologic and small molecule products across multiple therapeutic areas.
21Bronze Partners
Quintiles IMS
Contact Elisabeth Collins
Business Development Manager
Australia, New Zealand
Phone +61 (0) 468 970 450
Email Elisabeth.collins@quintilesims.com
Website quintilesims.com
COMPANY PROFILE
QuintilesIMS (QI) is a leading global healthcare provider of integrated information and
technology-enabled services. QI is dedicated to helping its clients improve their clinical,
scientific and commercial results. Formed through the merger of Quintiles and IMS Health,
QI’s approximately 50,000 employees conduct operations in more than 100 countries. QI
develops and implements solutions to help its clients maximize innovation and drive
healthcare forward.
Regeneus
Contact John Martin
Chief Executive Officer
Phone +61 2 9499 8010
Email john.martin@regeneus.com.au
Website regeneus.com.au
COMPANY PROFILE
Regeneus Ltd (ASX: RGS) is an Australian-based clinical-stage regenerative medicine
development company using stem cell and immune-oncology technologies to develop a
portfolio of innovative cell-based therapies across multiple technology platforms. Regeneus
seeks to treat significant unmet medical needs in the human and animal health markets
with an initial focus on osteoarthritis and other musculoskeletal disorders, oncology and
dermatology.
22Bronze Partner
Vudbenk Life Sciences
Contact Pál Forgács,
Phone +61 (0)449 033 881
Email ceo@vudbenk.com
Website vudbenk.com
COMPANY PROFILE
Vudbenk Life Science is a clinical stage biotech company pursuing the clinical research of a
synthetic small molecule, BGP-15. The company signed a license and sponsorship agreement
with a US biopharmaceutical enterprise having a long history of BGP-15-related research in
2015. Vudbenk Life Science is present in Australia and Hungary.
BGP-15 improves cell structure and optimises cell operation, thus it able to slow down the
development of muscular diseases, such as Duchenne muscular dystrophy and certain
cardiovascular diseases. The synthetic molecule is able to intensify the production of heat
shock proteins arising in response to environmental stress factors. The lack of these proteins
plays a key role in insulin resistance, causing type 2 diabetes.
23Australian and New Zealand organisations
attending BIO
360biolabs Brooker Consulting Pty Ltd
AbbVie Burnet Institute
Actinogen Medical Caldera Health Limited
AJ Park, Ltd Callaghan Innovation
Allens Patent & Trade Mark Attorneys Cancer Trials Australia
Alliance for Safe Biologic Medicines Catalyst Intellectual Property
Antisense Therapeutics Limited Catalyst Power Inc
Atomo Diagnostics Pty Ltd Catalyst Therapeutics
Auckland UniServices, Ltd Cellmid Limited
Aus Bio Ltd Centre for Eye Research Australia
AusBiotech, Ltd Certara
AusIndustry Clarity Pharmaceuticals
Australian Trade Commission Clinical Genomics
Avalia Immunotherapies Clinical Network Services (Cns) Pty Ltd
Baker Heart and Diabetes Institute Corrs Chambers Westgarth
Baldwins Intellectual Property CoSec Consulting
Baldwins Limited CPR Pharma Services Pty Ltd
Benitec Biopharma Ltd CreateIP
Bio Consultancy Pty Ltd CSIRO
Biocomm Squared PTY LTD CSL Behring
BioCurate Pty Ltd Cullens
Biointelect Pty Limited CuroNZ Limited
Bionomics Ltd Datapharm Australia Pty Ltd
BioPacific Partners Davies Collison Cave
Biotron Limited Deloitte
Bird & Bird LLP Deloitte Consulting LLP
Brandon Capital Partners DibbsBarker
*List current at 5 June 2017
24Australian and New Zealand organisations
attending BIO
DLA Piper Australia LuinaBio
Ellume Marilyn Careers
Emeritus Research Medical Developments International
EY Medicines Australia
FB Rice Merck
FPA Patent Attorneys Molecule2Market
Genome.One Monash University
Global Biosolutions MTPConnect
Gold Coast Health & Knowledge Precinct Murdoch Childrens Research Institute
Government of Victoria - Melbourne, Neuclone
Griffith University Neuroscience Trials Australia
Henry Hughes Intellectual Property New Zealand Pharma
Hexima Nexomics
Hikurangi Bioactives Novotech
HoneyLab Nucleus Network
I D E Group OccuRx Pty Ltd
IDT CMAX oNKo-innate
Imagion Biosystems Otago Innovation Limited
Implicit Bioscience, Ltd Pacific Edge Ltd
INC Research Paradigm BioPharmaceuticals
James & Wells Petri Exchange
James Cook University Pharmaceutical Packaging Professionals
Johnson & Johnson Pharmaceutical Solutions Ltd
Kode Biotech Limited Pharmasia News
Lendlease Pharmaxis, Ltd
Life Sciences Queensland Ltd Phebra Pty Limited
Linear Clinical Research Phillips Ormonde & Fitzpatrick
Loxegen Pty Ltd Phosphagenics Ltd
25Australian and New Zealand organisations
attending BIO
Pizzeys Patent and Trade Mark Attorneys Pty
Ltd Spruson & Ferguson
Planet Innovation Inc St Vincent's Hospital Melbourne
Plunkett Consulting Group Suda Ltd
Prime Accounting & Business Advisory Sypharma
QIMR Berghofer Medical Research Institute The University of Melbourne
QUE Oncology, Inc. The University of Queensland
The Walter & Eliza Hall Institute of
Queensland Government Medical Research
Queensland University of Technology Thinkable
QuintilesIMS Thomson Geer Lawyers
Race Oncology Ltd. Translational Research Institute (TRI)
Regeneus Ltd UniQuest Pty Limited
Scientia Clinical Research University of Southern Queensland
SCY Consulting Ltd University Western Australia
Sementis Ltd Upside Biotechnologies Ltd.
Shelbourne Chambers Upstream Medical Technologies
Shelston IP UQ Research Institutes
Silver Fern Farms Limited Vectus Biosystems
Southern Cross University Vudbenk Life Science Australia Pty Ltd
Southern Oil Refining Pty Ltd Wallonia Export-Investment Agency
Southern Star Research Watermark Intellectual Property Pty Ltd
Specialised Therapeutics Wrays
2627
Australia Pavilion
#4707
Contact AusBiotech
admin@ausbiotech.org
ausbiotech.org
+61 3 9828 1400
28You can also read
